1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Zhejiang Ausun Pharmaceutical Co., Ltd.

Zhejiang Ausun Pharmaceutical Co., Ltd.

603229.SS
Zhejiang Ausun Pharmaceutical Co., Ltd.CN flagShanghai Stock Exchange
8.11
CNY
-0.37
- -
6.73BMarket Cap
Zhejiang Ausun Pharmaceutical Co., Ltd.
603229.SS
(Shanghai Stock Exchange)

Recent

price

8.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.5
0.59
0.91
0.52
0.36
0.36
0.33
0.41
0.55
0.72
0.95
1
0.96
0.97
0.92
Revenue per Share
0.02
0.08
0.1
0.12
0.1
0.08
0.06
0.08
0.12
0.18
0.29
0.31
0.25
0.16
0.23
Basic EPS, GAAP
-0.33
-0.1
-0.01
0.02
0.09
-0.01
-0.06
0.05
0.06
-0.17
-0.19
0.07
0.08
0.06
-0.13
Free Cash Flow per Basic Share
0.02
0.02
0.02
0.01
0.01
- -
0.02
0.02
0.02
0.03
0.05
0.07
0.1
0.11
0.1
Dividend per Share
0.09
0.15
0.27
0.32
0.42
0.48
0.46
0.52
0.72
0.88
1.23
1.66
2.06
2.12
2.2
Book Value per Share
-0.17
-0.02
0.18
0.3
0.37
0.8
0.75
0.82
1.43
1.38
1.63
2.43
2.56
2.6
2.67
Tangible Book Value per Share
117
205
220
501
551
660
749
743
745
795
804
819
827
816
851
Basic Weighted Avg Shares
59
121
201
263
199
240
244
308
409
570
765
817
795
793
785
Sales/Revenue/Turnover
10.41
20.28
17.53
27.77
28.73
32.41
12.51
19.39
29.48
28
28
32.09
25.89
17.49
23.15
Operating Margin (%)
3
8
11
11
15
18
21
23
25
30
34
41
64
74
- -
Depreciation Expense
2
16
22
61
57
53
44
56
87
146
235
254
207
131
196
Net Income, GAAP
17.3
14.88
21.73
13.38
12.15
11.86
7.31
6.96
9.07
8.45
8.01
12.68
13.91
5.32
13.64
Effective Tax Rate (%)
3.89
12.86
10.67
23.17
28.83
22.07
17.99
18.31
21.22
25.62
30.79
31.09
26
16.47
25.01
Profit Margin (%)
-49
-70
-71
9
54
339
340
369
736
490
391
904
1,035
1,079
1,205
Working Capital
36
27
- -
5
13
- -
- -
- -
- -
45
73
2
1
44
20
LT Debt
10
33
78
188
243
565
598
645
1,127
1,255
1,461
2,142
2,272
2,269
2,426
Total Equity
- -
25.37
20.82
31.09
18.28
15.8
4.6
8.21
11.82
11.5
12.83
11.02
7.1
4.99
5.94
Return on Invested Capital (%)
- -
24.42
21.42
36.87
23.79
18.17
12.7
13.81
17.49
21.35
23.65
18.02
11.73
6.64
10.28
Return on Capital (%)
- -
75.43
46.93
55.51
29.5
19.37
13.22
15.37
18.85
23.75
27.92
21.6
13.5
7.6
11.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
271
291
312
LT Borrowings
- -
- -
19
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
830
830
830
Market Capitalization
8,026
7,033
7,424

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,709
1,836
1,862
Cash, Cash Equivalents & STI
1,099
1,110
1,151
Accounts Receivable, Net
192
327
280
Inventories
401
384
402
Total Current Liabilities
675
714
657
Payables & Accruals
- -
- -
- -
ST Debt
271
291
312
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.03%
16.07%
-0.11%
Free Cash Flow
31%
-107.33%
-21.85%
Net Income, GAAP
13.38%
16.36%
-36.86%
Sales/Revenue/Turnover
13.45%
15.46%
-0.32%
Total Cash Common Dividend
60.43%
48.88%
7.61%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
301
191
198
105
795
2025
307
175
147
- -
793
2026
309
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
- -
- -
- -
0.25
2025
0.14
- -
- -
- -
0.16
2026
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.11
2026
- -
- -
- -
- -
- -
Similar Companies
Citius Pharmaceuticals Inc (CTXRW)
XORTX Therapeutics Inc. (XRTX)
Abivax S.A. (0RA9.L)
TuHURA Biosciences, Inc. (HURA)
SkinBioTherapeutics Plc (SBTX.L)
Tryp Therapeutics Inc. (TRYPF)
Business
Zhejiang Ausun Pharmaceutical Co., Ltd. engages primarily in the research, development, manufacturing, and sale of pharmaceutical products and healthcare-related solutions. The company's core offerings include cardiovascular medications; diabetes treatment drugs; digestive system therapeutics; anti-inflammatory and analgesic agents; traditional Chinese medicine formulations; biochemical reagents; and health supplements. It serves both hospital and retail pharmacy markets with a diversified product portfolio across these therapeutic areas. The company operates predominantly in China, with its headquarters based in Zhejiang Province, where it was founded. In the last 1-2 years, Zhejiang Ausun Pharmaceutical has focused on strengthening its R&D capabilities and expanding its product development pipeline, notably launching new drugs in key therapeutic segments such as cardiovascular and metabolic diseases. It has formed strategic partnerships with research institutions and biotechnology firms to innovate in drug formulation and to accelerate commercialization of advanced pharmaceutical products. Additionally, the company has invested in upgrading its manufacturing processes to comply with international standards, aiming to enhance product quality and scale its geographic reach. No major name changes or corporate reorganizations have been reported during this period. Zhejiang Ausun Pharmaceutical operates within the pharmaceutical industry, targeting healthcare providers, hospitals, and pharmaceutical distributors in the Chinese market. It was established in 1997 and is listed on the Shanghai Stock Exchange under ticker 603229.SS. The company maintains several subsidiaries that support its operations in research, manufacturing, and distribution, reflecting its vertical integration strategy to control the supply chain and enhance market responsiveness. Overall, Zhejiang Ausun adheres to a model focused on innovation-driven growth in specialized pharmaceutical products for chronic and acute disease management.